Severe meningococcal shock with purpura fulminans: Untoward result of genetic polymorphisms?;Purpura fulminans méningococcique: Rencontre malheureuse de polymorphismes génétiques?

Archives de Pediatrie

Volumn 8, Issue 8, 2001, Pages 843-852

  Mercier, J C ^a   Bingen, E ^a   Schlegel, N ^a   Elion, J ^a   Casanova, J L ^b   Mira, J P ^c   Beaufils, F ^a  

^a HÔPITAL ROBERT DEBRÉ   (France)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

^c Hôpital Cochin ^*  (France)

Author keywords

Coagulation protein disorders; Cytokine; Genetic predisposition to disease; Meningococcal infections; Purpura fulminans; Shock, septic

Indexed keywords

ANTIBIOTIC AGENT; INTERLEUKIN 10; LECTIN; MANNOSE BINDING PROTEIN; MENINGOCOCCUS VACCINE; PLASMINOGEN ACTIVATOR INHIBITOR 1; TUMOR NECROSIS FACTOR ALPHA;

CLINICAL FEATURE; CYTOKINE RELEASE; DIAGNOSTIC PROCEDURE; DISEASE COURSE; EARLY DIAGNOSIS; FULMINATING PURPURA; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; HEMODYNAMICS; HUMAN; IMMUNOTHERAPY; INTENSIVE CARE; MENINGOCOCCEMIA; MORTALITY; NEISSERIA MENINGITIDIS; REVIEW; SEPTIC SHOCK;

EID: 0034897694     PISSN: 0929693X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0929-693X(01)00529-2     Document Type: Short Survey

References (92)

1. Mémoire sur la maladie qui a régné à Genève au printemps de 1805
2. Où en est-on avec le purpura fulminans?
3. Update on meningococcal disease with emphasis on pathogenesis and clinical management
4. Meningococcal conjugate vaccines: New opportunities and new challenges
5. Features and outcome in meningococcal disease presenting with maculopapular rash
6. Pathophysiology, treatment and outcome of meningococcemia: A review and recent experience
7. Hemodynamic patterns of meningococcal shock in children
8. Scores de gravité à l'admission des méningococcémies
9. Cerebrospinal fluid pleocytosis and prognosis in invasive meningococcal disease in children
10. Pediatric risk of mortality (PRISM) score in meningococcal disease
11. PRISM III: An updated pediatric risk of mortality score
12. Paediatric index of mortality (PIM): A mortality prediction model for children in intensive care
13. Explorations hémodynamiques et échocardiographiques des méningococcies graves de l'enfant
14. Myocardial dysfunction in children with acute meningococcemia
15. Life-threatening heart failure in meningococcla septic shock in children: Non-invasive measurement of cardiac parameters is of important prognostic value
16. Profound but reversible myocardial depression in patients with septic shock
17. Influence of a myocardial depressant factor on physiologic properties of cardiac muscle
18. A circulating myocardial depressant substance in humans with septic shock. Septic shock patients with a reduced ejection fraction have a circulating factor that depresses in vitro myocardial cell performance
19. Left ventricular systolic and diastolic dysfunction after infusion of tumor necrosis factor-? in conscious dogs
20. Tumour necrosis factor-? and interleukin-1β are responsible for in vitro myocardial cell depression induced by human septic shock
21. The L-arginine - Nitric oxide pathway
22. Negative inotropic effects of cytokines on the heart mediated by nitric oxide
23. Nitric oxide and cardiac function
24. The cardiovascular response of normal humans to the administration of endotoxin
25. The proinflammatory cytokines interleukin-1 and tumor necrosis factor and treatment of the septic shock syndrome
26. Dissociation between plasma and monocyte-associated cytokinbes during sepsis
27. Type-specific and cross-reactivity antibodies in gram-negative bacteremia
28. Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli
29. Treatment of severe infectious purpura in children with human plasma from donors immunized with Escherichia coli J5: A prospective double-blind study
30. Tumor necrosis factor and interleukin-1 in the serum of children with severe infectious purpura
31. Imbalance between tumour necrosis factor-alpha and soluble TNF receptor concentrations in severe meningococcemia
32. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin
33. Randomized, placebo-controlled trial of HA-1A, a human monoclonal antibody to endotoxin, in children with meningococcal septic shock
34. Preliminary evaluation of recombinant amino-terminal fragment of human bactericidal/permeability-increasing protein in children with severe meningococcal sepsis
35. Adjunctive therapy for septic shock: A review of experimental approaches
36. Sepsis trials. Intersection of investigation, regulation, funding, and practice
37. Release of tumor necrosis factor: An innate host characteristic that may contribute to the outcome of meningococcal disease
38. Genetic influence on cytokine production and fatal meningococcal disease
39. Anti-inflammatory cytokine profiles and mortality in febrile patients
40. Surgical intervention for the complications of meningococal-induced purpura fulminans
41. The role of heparin in the prevention of extremity and digit necrosis in meningococcal purpura fulminans
42. Topical nitroglycerin and pain in purpura fulminans
43. Use of protein-C concentrate, heparin, and haemodiafiltration in meningococcus-induced purpura fulminans
44. Recombinant tissue plasminogen activator treatment in two infants with fulminant meningococcemia
45. Recombinant tissue plasminogen activator restores perfusion in meningococcal purpura fulminans
46. Disseminated intravascular coagulation
47. Effect of the factor V Leiden mutation on the severity of meningococcal disease
48. 4G/5G promoter polymorphism in the plasminogen-activator-inhibitor-1 gene and outcome of meningococcal disease
49. Population genetics and molecular epidemiology of Neisseria meningitidis
50. Antigenic and epidemiologic properties of the ET-37 complex of Neisseria meningitidis
51. Serogroup C meningococcal outbreaks in the United States. An emerging threat
52. Serogroup Y meningococcal disease in Chicago, 1991-1997
53. Complement deficiency predisposes for meningitis due to nongroupable meningococci and Neisseria-related bacteria
54. Multiloculus sequence typing: A portable approach to the identification of clones within populations of pathogenic microorganisms
55. Uncloacking the meningococcus: Dynamics of carriage and disease
56. Update on meningococcal disease with emphasis on pathogenesis and clinical management
57. Jails, microbes and the three-foot barrier
58. Clonal diversity of Neisseria meningitidis from a population of asymptomatic carriers
59. Identification of nasopharyngeal carriage of an outbreak strain of Neisseria meningitidis by pulsed-field gel electrophoresis versus phenotypic methods
60. Asymptomatic carriage of Neisseria meningitidis in a randomly sampled population
61. Pathogenic Neisseriae: Complexity of pathogen-host cell interplay
62. Pathogenic events during infection of the human nasopharynx with Neisseiria meningitidis and Haemophilus influenzae
63. Membrane cofactor protein (MCP or CD46) is a cellular pilus receptor for pathogenic Neisseria
64. Infection of the epithelial cells by pathogenic Neisseriae reduces the levels of multiple lysosomal constituents
65. Meningococcal disease and influenza-like syndrome: A new approach to an old question
66. The influence of capsulation and lipopolysaccharide structure on neutrophil adhesion molecule expression and endothelial injury by Neisseria meningitidis
67. Complement deficiency predisposes for meningitis due to nongroupable meningococci and Neisseiria-related bacteria
68. Association of variants of the gene for mannose-binding lectin with susceptibility to meningococcal disease
69. Meningococcal infections: Reducing the case fatality rate by giving penicillin before admission to hospital
70. Early treatment with parenteral penicillin in meningococcal disease
71. Reducing mortality from meningococcal disease. Give antibiotics before admission
72. Épidémiologie de la résistance du méningocoque aux β-lactamines: Mécanismes de résistance et conséquences thérapeutiques
73. Antibiotic-induced release of endotoxin: A reappraisal
74. No increase in endotoxin release during antibiotic killing of meningococci
75. Severity of meningococcal disease: Assessment by factors and scores and implications for patient management
76. Are paediatricians ovetreating suspected meningococcal disease?
77. Earlier recognition of meningococcal disease may contribute to improved outcomes
78. Chemoprophylaxis for bacterial infections: Principle of and application to meningococcal infections
79. Secondary cases of meningococcal infection among close family and household contacts in England and Wales
80. Meningococcal disease in Belgium. Secondary attack rate among household, day-care nursery and pre-elemententary school contacts
81. Comparative efficaciy of ceftriaxone and rifampin in eradicating pharyngeal carriage of group A Neisseria meningitidis
82. Does eradication of meningococcal carriage in household contacts prevent secondary case of meningococcal disease?
83. Reactogenicity and immunogenicity of a quadrivalent combined meningococcal polysaccharide vaccine in children
84. Control of an outbreak of group C meningococcal meningitis with a polysaccharide vaccine
85. Priority during a meningitis epidemic: Vaccination or treatment?
86. Meningococcal conjugate vaccines: New opportunities and new challenges
87. Enhanced surveillance of invasive Haemophilus influenzae type b in England, to 1996: Impact of conjugate vaccines
88. Complete DNA sequence of a serogroup A strain of Neisseria meningitidis Z2491
89. Complete genome sequence of Neisseria meningitidis serogroup B strain MC58
90. Identification of vaccine candidates against sero-group B meningococcus by whole-genome sequencing
91. Immunogenicity and reactogenicity in UK infants of a novel meningococcal vesicle vaccine containing multiple class 1 (PorA) outer membrane proteins
92. Are natural anticoagulants candidates for modulating the inflammatory response to endotoxin?